Duvelisib [1201438-56-3]
Cat# HY-17044-50mg
Size : 50mg
Brand : MedChemExpress
Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.
For research use only. We do not sell to patients.
Duvelisib Chemical Structure
CAS No. : 1201438-56-3
*
This product is a controlled substance and not for sale in your territory.
- •Nat Metab. 2020 Dec;2(12):1427-1442. [Abstract]
- •Nat Commun. 2020 Apr 14;11(1):1792. [Abstract]
- •Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- •Cell Syst. 2018 Apr 25;6(4):424-443.e7. [Abstract]
- •OncoImmunology. 11 Oct 2022.
- •Arab J Chem. 2023 Jul 4, 105117.
- •bioRxiv. 2023 May 16.
Biological Activity
Purity & Documentation
References
Customer Review
Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively. | ||||
| ||||
In Vitro | PI3Kδ and PI3Kγ inhibition with Duvelisib (IPI-145) has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with Duvelisib inhibits both adhesion and migration of AML blasts to bone marrow stromal cells. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. | |||
---|---|---|---|---|
|
-
[1]. Pillinger G, et al. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget. 2016 Jun 28;7(26):39784-39795.
[2]. G?ckeritz E, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015 Nov 1;137(9):2234-42.
* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 years; -20°C, 6 months. When stored at -80°C, please use it within 1 years. When stored at -20°C, please use it within 6 months.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 2.3989 mL | 11.9944 mL | 23.9889 mL | 59.9722 mL |
5 mM | 0.4798 mL | 2.3989 mL | 4.7978 mL | 11.9944 mL | |
10 mM | 0.2399 mL | 1.1994 mL | 2.3989 mL | 5.9972 mL | |
15 mM | 0.1599 mL | 0.7996 mL | 1.5993 mL | 3.9981 mL | |
20 mM | 0.1199 mL | 0.5997 mL | 1.1994 mL | 2.9986 mL | |
25 mM | 0.0960 mL | 0.4798 mL | 0.9596 mL | 2.3989 mL | |
30 mM | 0.0800 mL | 0.3998 mL | 0.7996 mL | 1.9991 mL | |
40 mM | 0.0600 mL | 0.2999 mL | 0.5997 mL | 1.4993 mL | |
50 mM | 0.0480 mL | 0.2399 mL | 0.4798 mL | 1.1994 mL | |
60 mM | 0.0400 mL | 0.1999 mL | 0.3998 mL | 0.9995 mL | |
80 mM | 0.0300 mL | 0.1499 mL | 0.2999 mL | 0.7497 mL |
- PI3K/Akt/mTOR
- PI3K
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Keywords:
Duvelisib1201438-56-3IPI-145 INK1197IPI145IPI 145INK1197INK 1197INK-1197PI3KPhosphoinositide 3-kinaseInhibitorinhibitorinhibit
Your Recently Viewed Products:
Inquiry Online
Your information is safe with us. * Required Fields.
Bulk Inquiry
Inquiry Information
- Product Name:
- Duvelisib
- Cat. No.:
- HY-17044
- Quantity:
- MCE Japan Authorized Agent: